We speculate that higher serum sST2 concentrations after MI may cause a worse prognosis because sST2 blocks the beneficial effects of IL-33, such as reducing fibrosis and hypertrophy, preventing apoptosis, preserving ventricular function, and improving survival (52). The gene discussed is IL33; the disease is myocardial infarction.